sponsored
PatientsVille.com Logo

PatientsVille

Vospire Medical Research Studies

Up-to-date List of Vospire Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest Vospire Medical Research Studies

Rank Status Study
1 Not yet recruiting Adding Nebulized Salbutamol to Intravenous Atropine and Oxygen in OP Poisoning
Conditions: Salbutamol;   Organophosphate Poisoning;   Atropine
Interventions: Drug: ventolin 2.5 mg;   Drug: ventolin 5 mg;   Drug: Atropine and Oxygen
Outcome Measures: Improvement of oxygen saturation;   Heart rate, respiratory rate and Blood pressure
2 Recruiting Salbutamol, Pharmacogenetics and Breathing Mechanics
Conditions: Exercise-induced Bronchoconstriction,;   Inhaled Salbutamol;   Cycling Performance
Interventions: Drug: Salbutamol;   Drug: Placebo
Outcome Measures: The effect of inhaled salbutamol on mean power output during cycling performance in female and male athletes;   The effect of inhaled salbutamol on work of breathing (WOB) and expiratory flow limitation (EFL) in female and male athletes;   The effect of inhaled salbutamol on minute ventilation in asthmatic and non-asthmatic trained, female and male cyclists
3 Not yet recruiting The Various Effects of Gaseous Albuterol on Serum Lactate
Condition: Asthma
Interventions: Drug: Normal Saline;   Drug: Albuterol
Outcome Measure: Number of subjects with a change from baseline serum lactate following a one hour albuterol nebulizer treatment.
4 Not yet recruiting A Study of Levalbuterol Tartrate HFA Inhalation Aerosol Metered Dose Inhaler (MDI) in Pediatric Subjects
Condition: Asthma
Interventions: Drug: levalbuterol tartrate HFA inhalation aerosol;   Drug: placebo
Outcome Measures: The overall safety of treatment with levalbuterol tartrate HFA inhalation aerosol as measured by the number and percentage of subjects with treatment-emergent adverse events.;   The overall safety of treatment with levalbuterol tartrate HFA inhalation aerosol as measured by the number and percentage of subjects with serious adverse events.;   The overall safety of treatment with levalbuterol tartrate HFA inhalation aerosol as measured by the number and percentage of subjects with treatment-emergent adverse events leading to discontinuation.;   Change from baseline in Pulmonary Score (total score) to end of treatment;   Change from baseline in Pulmonary Score (individual component scores) to end of treatment;   Change from baseline in Pulmonary Score (total score) after each dose;   Change from baseline in Pulmonary Score (individual component scores) after each dose;   Number and percentage of subjects determined to be stabilized after treatment
5 Unknown  Dose Finding Study of Albuterol Sulfate in Patients With Intermittent or Persistent Mild Asthma
Condition: Asthma
Interventions: Drug: albuterol sufate DPI (TBS-7) dose 1;   Drug: albuterol sufate DPI (TBS-7) dose 2;   Drug: albuterol sufate DPI (TBS-7) dose 3;   Other: Placebo;   Drug: Albuterol
Outcome Measures: forced expiratory volume at one second;   PK parameters;   safety and tolerability
6 Recruiting Efficacy and Safety of Increasing Doses of Inhaled Albuterol Administered by Metered Dose Inhalers in Children With Acute Wheezing Episodes
Conditions: Asthma;   Children
Interventions: Drug: Albuterol - Experimental;   Drug: Albuterol - Control
Outcome Measures: Hospital Admission;   Forced expiratory volume in the first second;   Change in PRAM score;   Albuterol determination in the plasma;   Dosage of glucose and potassium plasma levels;   Electrocardiogram;   Respiratory frequency;   Need for additional therapies
7 Unknown  Hypertonic Saline for Outpatient Bronchiolitis
Conditions: Bronchiolitis;   Respiratory Distress
Interventions: Drug: Inhalation of salbutamol diluted in hypertonic saline;   Drug: Inhalation of salbutamol diluted in normal saline
Outcome Measures: Change in the respiratory distress score (Tal) between the basal score and the final score after 3 salbutamol nebulizations;   Change in the respiratory distress score (Tal) between the basal score and the first nebulization;   Change in the respiratory distress score (Tal) between the basal score and the second nebulization;   Change in pulse oxymetry reading between the basal score and after each of the three nebulizations;   Change in cardiac frequency, irritability, general condition or anything else between the basal score and the first, second and third nebulization
8 Recruiting Nebulized or Inhaled Albuterol for Lymphangioleiomyomatosis
Condition: Lymphangioleiomyomatosis
Interventions: Drug: albuterol inhaler;   Procedure: PFT;   Drug: albuterol nebulizer
Outcome Measure: Greater improvement in lung function with nebulized albuterol.
9 Unknown  Genetic Determinants of the Response to Salbutamol Among Asthma Patients
Condition: Asthma
Intervention: Drug: Albuterol
Outcome Measures: Change in lung function tests after salbutamol inhalation;   Change in blood pressure and pulse after salbutamol inhalation
10 Recruiting Inhaler Lung Deposition in Chronic Obstructive Pulmonary Disease (COPD)
Conditions: CHRONIC OBSTRUCTIVE PULMONARY DISEASE;   ASTHMA;   HEALTHY SUBJECTS
Intervention: Drug: SALBUTAMOL
Outcome Measures: ANALYSIS OF LUNG DEPOSITION - Penetration Index;   ANALYSIS OF LUNG PHYSIOLOGY TESTS - Impulse Oscillometry R5 & X5 and Multi-breath Washout tests of S-acin and S-cond
11 Not yet recruiting Albuterol and Dynamic Hyperinflation in Idiopathic Pulmonary Arterial Hypertension
Condition: Idiopathic Pulmonary Arterial Hypertension.
Interventions: Drug: Albuterol.;   Drug: Normal saline placebo
Outcome Measures: End-expiratory lung volume:total lung capacity (EELV/TLC) ratio at matched metabolic isowork.;   Change in peak oxygen consumption with albuterol;   Change in O2 pulse with albuterol.;   Exercise time;   Borg dyspnea score
12 Recruiting IPF Drug Deposition Study
Condition: Idiopathic Pulmonary Fibrosis
Intervention: Drug: Salbutamol
Outcome Measures: Total lung deposition;   Serum salbutamol change;   Urinary salbutamol concentration;   Penetration index
13 Recruiting Inhaled Salbutamol in Elective Caesarean Section
Conditions: Postnatal Pulmonary Adaptation;   Cesarean Section
Interventions: Drug: salbutamol;   Drug: Placebo
Outcome Measures: To evaluate whether lung ultrasound at 30-60 minutes of birth is improved at 3-6 hours of birth;   To evaluate whether lung compliance measured at 3-6 hours is improved by inhaled salbutamol at 30-60 minutes of age;   Decrease in respiratory rate at 3-6 hours of age;   To see whether there is a correlation between airway ENaC expression measured at 30-60 minutes of age and consequent lung fluid content at 3-6 hours of age;   Whether cord blood cortisol concentrations correlate with expression of ENaC and further, with decrease in lung fluid content at 3-6 hours of age
14 Not yet recruiting Effectiveness of Routine Nebulisation of Mucolitycs and Bronchodilators During Mechanical Ventilation
Condition: Respiratory Failure
Interventions: Drug: acetylcysteine and salbutamol;   Drug: acetylcysteine;   Drug: salbutamol
Outcome Measures: Number of ventilator-free days at day 28;   Length of stay;   Mortality;   Pulmonary complications;   Side effects
15 Unknown  Genetic Determinants of the Bronchodilatation Effect of Albuterol ex-Vivo
Condition: Asthma
Intervention: Drug: albuterol
Outcome Measures: The extent of bronchial dilatation ex-vivo;   The extent of decrease in brochial dilatation after prolonged incubation with albuterol
16 Recruiting Bronchoprotection of Salbutamol in Asthma and Chronic Obstructive Pulmonary Disease
Conditions: Asthma;   COPD
Intervention: Drug: salbutamol
Outcome Measure: methacholine PC20 dose shift
17 Unknown  Acute Asthma Responsiveness and B2 Adrenergic Receptors Polymorphisms
Condition: Acute Asthma
Intervention:
Outcome Measures: B2AR polymorphisms associated with albuterol responsiveness in acute asthma.;   B2AR haplotypes
18 Unknown  Genetic Determinants of the Hypokalemic and Hyperglycemic Effect of Albuterol Inhalation
Conditions: Hyperkalemia;   Chronic Renal Failure
Intervention: Drug: Albuterol (1,200 μg) through metered-dose inhaler
Outcome Measures: The extent of decrease in plasma potassium concentration;   The extent of increase in plasma glucose concentration;   Plasma concentration of albuterol
19 Unknown  Effect of the Salbutamol on Mechanical Properties of Respiratory System
Conditions: Smoking;   Airway Obstruction
Intervention: Drug: Salbutamol sulphate
Outcome Measures: Respiratory function test;   Salbutamol
20 Recruiting Safety and Efficacy of Albuterol on Motor Function in Individuals With Late-onset Pompe Disease Receiving Enzyme Replacement Therapy
Condition: Pompe Disease
Interventions: Drug: Albuterol;   Drug: Placebo
Outcome Measures: Number of participants with Adverse Events.;   Change in forced vital capacity from pulmonary function tests at 30 weeks and 52 weeks.;   Change in 6 minute walk test

These studies may lead to new treatments and are adding insight into Vospire etiology and treatment.

A major focus of Vospire research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.


Discuss Vospire